Chinese Journal of Dermatology ›› 2017, Vol. 50 ›› Issue (11): 855-859.doi: 10.3760/cma.j.issn.0412-4030.2017.11.022
• Reviews • Previous Articles Next Articles
Cheng Hao
Received:
2017-09-21
Revised:
2017-10-26
Online:
2017-10-15
Published:
2017-11-02
Cheng Hao. Prophylactic human papillomavirus vaccines[J]. Chinese Journal of Dermatology, 2017, 50(11): 855-859.doi:10.3760/cma.j.issn.0412-4030.2017.11.022
[1] | zur Hausen H. Papillomaviruses in the causation of human cancers -a brief historical account[J]. Virology, 2009, 384(2): 260⁃265. DOI: 10.1016/j.virol.2008.11.046. |
[2] | Drolet M, Bénard É, Boily MC, et al. Population⁃level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta⁃analysis[J]. Lancet Infect Dis, 2015, 15(5): 565⁃580. DOI: 10.1016/S1473⁃3099(14)71073⁃4. |
[3] | Bernard HU, Burk RD, Chen Z, et al. Classification of papillo⁃maviruses (PVs) based on 189 PV types and proposal of taxonomic amendments[J]. Virology, 2010, 401(1): 70⁃79. DOI: 10.1016/j.virol.2010.02.002. |
[4] | Van Doorslaer K, Li Z, Xirasagar S, et al. The Papillomavirus Episteme: a major update to the papillomavirus sequence database[J]. Nucleic Acids Res, 2017, 45(D1): D499⁃499D506. DOI: 10.1093/nar/gkw879. |
[5] | de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta⁃analysis[J]. Lancet Infect Dis, 2007, 7(7): 453⁃459. DOI: 10.1016/S1473⁃3099(07)70158⁃5. |
[6] | Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner[J]. J Infect Dis, 2008, 197(2): 279⁃282. DOI: 10.1086/524875. |
[7] | Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta⁃analysis of 1 million women with normal cytological findings[J]. J Infect Dis, 2010, 202(12): 1789⁃1799. DOI: 10.1086/657321. |
[8] | Cubie HA. Diseases associated with human papillomavirus infection[J]. Virology, 2013, 445(1⁃2): 21⁃34. DOI: 10.1016/j.virol.2013.06.007. |
[9] | World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014[J]. Wkly Epidemiol Rec, 2014, 89(43): 465⁃491. |
[10] | Bruni L, Barrionuevo⁃Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Botswana. Summary Report 27 July 2017. |
[11] | Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008[J]. Sex Transm Dis, 2013, 40(3): 187⁃193. DOI: 10.1097/OLQ.0b013e318286bb53. |
[12] | de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva[J]. Eur J Cancer, 2013, 49(16): 3450⁃3461. DOI: 10.1016/j.ejca.2013.06.033. |
[13] | De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta⁃analysis[J]. Int J Cancer, 2009, 124(7): 1626⁃1636. DOI: 10.1002/ijc.24116. |
[14] | Harper DM, DeMars LR. HPV vaccines ⁃ A review of the first decade[J]. Gynecol Oncol, 2017, 146(1): 196⁃204. DOI: 10.1016/j.ygyno.2017.04.004. |
[15] | Naud PS, Roteli⁃Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV⁃16/18 AS04⁃adjuvanted vaccine: final analysis of a long⁃term follow⁃up study up to 9.4 years post⁃vaccination[J]. Hum Vaccin Immunother, 2014, 10(8): 2147⁃2162. DOI: 10.4161/hv.29532. |
[16] | World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017 [J]. Wkly Epidemiol Rec, 2017, 92(19): 241⁃268. |
[17] | Nygård M, Saah A, Munk C, et al. Evaluation of the long⁃term anti⁃human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine[J]. Clin Vaccine Immunol, 2015, 22(8): 943⁃948. DOI: 10.1128/CVI.00133⁃15. |
[18] | Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: asystematic review of 10 years of real⁃world experience[J]. Clin Infect Dis, 2016, 63(4): 519⁃527. DOI: 10.1093/cid/ciw354. |
[19] | Quadrivalent vaccine against human papillomavirus to prevent high⁃grade cervical lesions[J]. N Engl J Med, 2007, 356(19): 1915⁃1927. DOI: 10.1056/NEJMoa061741. |
[20] | Joura EA, Giuliano AR, Iversen OE, et al. A 9⁃valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372(8): 711⁃723. DOI: 10.1056/NEJMoa1405044. |
[21] | Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)⁃16/18 AS04⁃adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double⁃blind, randomised study in young women[J]. Lancet, 2009, 374(9686): 301⁃314. DOI: 10.1016/S0140⁃6736(09)61248⁃4. |
[22] | Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9⁃valent HPV vaccine[J]. Pediatrics, 2015, 136(1): e28⁃39. DOI: 10.1542/peds.2014⁃3745. |
[23] | Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)⁃6/11/16/18 vaccine on all HPV⁃associated genital diseases in young women[J]. J Natl Cancer Inst, 2010, 102(5): 325⁃339. DOI: 10.1093/jnci/djp534. |
[24] | Garland SM, Hernandez⁃Avila M, Wheeler CM, et al. Quadri⁃valent vaccine against human papillomavirus to prevent anogenital diseases[J]. N Engl J Med, 2007, 356(19): 1928⁃1943. DOI: 10.1056/NEJMoa061760. |
[25] | Wheeler CM, Skinner SR, Del RMR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04⁃adjuvanted vaccine in women older than 25 years: 7⁃year follow⁃up of the phase 3, double⁃blind, randomised controlled VIVIANE study[J]. Lancet Infect Dis, 2016, 16(10): 1154⁃1168. DOI: 10.1016/S1473⁃3099(16)30120⁃7. |
[26] | Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04⁃adjuvanted vaccine in women older than 25 years: 4⁃year interim follow⁃up of the phase 3, double⁃blind, randomised controlled VIVIANE study[J]. Lancet, 2014, 384(9961): 2213⁃2227. DOI: 10.1016/S0140⁃6736(14)60920⁃X. |
[27] | Kreimer AR, González P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial[J]. Lancet Oncol, 2011, 12(9): 862⁃870. DOI: 10.1016/S1470⁃2045(11)70213⁃3. |
[28] | Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV⁃16/18 AS04⁃adjuvanted vaccine in Chinese women aged 18⁃25 years: event⁃triggered analysis of a randomized controlled trial[J]. Cancer Med, 2017, 6(1): 12⁃25. DOI: 10.1002/cam4.869. |
[29] | Reisinger KS, Block SL, Lazcano⁃Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papilloma⁃virus types 6, 11, 16, 18 L1 virus⁃like particle vaccine in preadolescents and adolescents: a randomized controlled trial[J]. Pediatr Infect Dis J, 2007, 26(3): 201⁃209. |
[30] | Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)⁃16/18 AS04⁃adjuvanted vaccine in healthy boys aged 10⁃18 years[J]. J Adolesc Health, 2009, 44(1): 33⁃40. DOI: 10.1016/j.jadohealth.2008.10.002. |
[31] | Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males[J]. N Engl J Med, 2011, 364(5): 401⁃411. DOI: 10.1056/NEJMoa0909537. |
[32] | Draper E, Bissett SL, Howell⁃Jones R, et al. Neutralization of non⁃vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera[J]. Vaccine, 2011, 29(47): 8585⁃8590. DOI: 10.1016/j.vaccine.2011.09.021. |
[33] | Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross⁃neutralizing antibodies that may mediate cross⁃protection[J]. Vaccine, 2011, 29(11): 2011⁃2014. DOI: 10.1016/j.vaccine.2011.01.001. |
[34] | Malagón T, Drolet M, Boily MC, et al. Cross⁃protective efficacy of two human papillomavirus vaccines: a systematic review and meta⁃analysis[J]. Lancet Infect Dis, 2012, 12(10): 781⁃789. DOI: 10.1016/S1473⁃3099(12)70187⁃1. |
[35] | Maver PJ, Poljak M. Progress in prophylactic human papilloma⁃virus (HPV) vaccination in 2016: A literature review[J]. Vaccine, 2017. DOI: 10.1016/j.vaccine.2017.07.113. |
[36] | Draper E, Bissett SL, Howell⁃Jones R, et al. A randomized, observer⁃blinded immunogenicity trial of Cervarix® and Gardasil® Human Papillomavirus vaccines in 12⁃15 year old girls[J/OL]. PLoS One, 2013, 8(5): e61825. DOI: 10.1371/journal.pone.0061825. |
[37] | Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009⁃2013[J]. Emerg Infect Dis, 2016, 22(1): 56⁃64. DOI: 10.3201/eid2201.150736. |
[38] | Cuschieri K, Kavanagh K, Moore C, et al. Impact of partial bivalent HPV vaccination on vaccine⁃type infection: a population⁃based analysis[J]. Br J Cancer, 2016, 114(11): 1261⁃1264. DOI: 10.1038/bjc.2016.97. |
[39] | Godi A, Bissett SL, Miller E, et al. Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12⁃15 year old girls receiving cervarix® or gardasil® vaccine[J/OL]. PLoS One, 2015, 10(10): e0140926. DOI: 10.1371/journal.pone.0140926. |
[40] | Castellsagué X, Muñoz N, Pitisuttithum P, et al. End⁃of⁃study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24⁃45 years of age[J]. Br J Cancer, 2011, 105(1): 28⁃37. DOI: 10.1038/bjc.2011.185. |
[41] | Schwarz T, Spaczynski M, Kaufmann A, et al. Persistence of immune responses to the HPV⁃16/18 AS04⁃adjuvanted vaccine in women aged 15⁃55 years and first⁃time modelling of antibody responses in mature women: results from an open⁃label 6⁃year follow⁃up study[J]. BJOG, 2015, 122(1): 107⁃118. DOI: 10.1111/1471⁃0528.13070. |
[42] | Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case⁃control study nested within a population based screening programme in Australia[J]. BMJ, 2014, 348: g1458. |
[43] | Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population⁃based HPV vaccination program on cervical abnormalities: a data linkage study[J]. BMC Med, 2013, 11: 227. DOI: 10.1186/1741⁃7015⁃11⁃227. |
[44] | Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data[J]. Lancet Infect Dis, 2011, 11(1): 39⁃44. DOI: 10.1016/S1473⁃3099(10)70225⁃5. |
[45] | Baldur⁃Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow⁃up of young Danish women[J]. J Natl Cancer Inst, 2014, 106(3): djt460. DOI: 10.1093/jnci/djt460. |
[46] | Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica[J/OL]. PLoS One, 2013, 8(7): e68329. DOI: 10.1371/journal.pone.0068329. |
[47] | Guo T, Eisele DW, Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer[J]. Cancer, 2016, 122(15): 2313⁃2323. DOI: 10.1002/cncr.29992. |
[48] | Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case⁃control assessment of the vaccine adverse event reporting system (VAERS) database[J]. Immunol Res, 2017, 65(1): 46⁃54. DOI: 10.1007/s12026⁃016⁃8815⁃9. |
[49] | Arnheim⁃Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study[J]. BMJ, 2013, 347: f5906. |
[50] | Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine[J]. JAMA, 2009, 302(7): 750⁃757. DOI: 10.1001/jama.2009.1201. |
[51] | Human papillomavirus vaccines: WHO position paper, October 2014⁃Recommendations[J]. Vaccine, 2015, 33(36): 4383⁃4384. DOI: 10.1016/j.vaccine.2014.12.002. |
[52] | Kim DK, Riley LE, Harriman KH, et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2017[J]. Ann Intern Med, 2017, 166(3): 209⁃219. DOI: 10.7326/M16⁃2936. |
[53] | Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Recomm Rep, 2014, 63(RR⁃05): 1⁃30. |
[54] | Petrosky E, Bocchini JA, Hariri S, et al. Use of 9⁃valent human papillomavirus (HPV) vaccine: updated HPV vaccination recom⁃mendations of the advisory committee on immunization practices[J]. MMWR Morb Mortal Wkly Rep, 2015, 64(11): 300⁃304. |
[55] | Robinson CL, Romero JR, Kempe A, et al. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger ⁃ United States, 2017[J]. MMWR Morb Mortal Wkly Rep, 2017, 66(5): 134⁃135. DOI: 10.15585/mmwr.mm6605e1. |
[56] | Meites E, Kempe A, Markowitz LE. Use of a 2⁃dose schedule for human papillomavirus vaccination ⁃ updated recommendations of the advisory committee on immunization practices[J]. MMWR Morb Mortal Wkly Rep, 2016, 65(49): 1405⁃1408. DOI: 10.15585/mmwr.mm6549a5. |
[57] | Saslow D, Castle PE, Cox JT, et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors[J]. CA Cancer J Clin, 2007, 57(1): 7⁃28. |
[58] | Bosch FX, Robles C, Díaz M, et al. HPV⁃FASTER: broadening the scope for prevention of HPV⁃related cancer[J]. Nat Rev Clin Oncol, 2016, 13(2): 119⁃132. DOI: 10.1038/nrclinonc.2015.146. |
[59] | Kim KS, Park SA, Ko KN, et al. Current status of human papillomavirus vaccines[J]. Clin Exp Vaccine Res, 2014, 3(2): 168⁃175. DOI: 10.7774/cevr.2014.3.2.168. |
[60] | Gupta G, Glueck R, Rishi N. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles[J]. Biologicals, 2017, 46: 11⁃22. DOI: 10.1016/j.biologicals.2016.12.002. |
[61] | Schellenbacher C, Roden RB, Kirnbauer R. Developments in L2⁃based human papillomavirus (HPV) vaccines[J]. Virus Res, 2017, 231: 166⁃175. DOI: 10.1016/j.virusres.2016.11.020. |
[62] | Schellenbacher C, Kwak K, Fink D, et al. Efficacy of RG1⁃VLP vaccination against infections with genital and cutaneous human papillomaviruses[J]. J Invest Dermatol, 2013, 133(12): 2706⁃2713. DOI: 10.1038/jid.2013.253. |
No related articles found! |
|